Loading...
•
Dec 31, 2023
Cerus Q4 2023 Earnings Report
Cerus reported sequential revenue growth, driven by North American sales, and narrowed its GAAP net loss, achieving adjusted EBITDA breakeven.
Key Takeaways
Cerus Corporation announced its Q4 and full-year 2023 financial results, highlighting sequential revenue growth in the fourth quarter driven by North American sales. The company narrowed its GAAP net loss attributable to Cerus Corporation to $1.3 million for the fourth quarter and achieved its goal of adjusted EBITDA breakeven for the fourth quarter. Cerus is reiterating its full-year 2024 product revenue guidance range of $172-175 Million.
Fourth-quarter product revenue increased to $46.8 million, driven by INTERCEPT platelets growth in North America.
Net loss attributable to Cerus Corporation narrowed to $1.3 million.
Adjusted EBITDA reached positive $4.7 million, surpassing breakeven.
Cash and cash equivalents and short-term investments totaled $65.9 million at the end of the year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Cerus expects full-year 2024 product revenue will be in the range of $172 million to $175 million. Included in this range is full-year 2024 INTERCEPT Fibrinogen Complex revenue guidance between $8 million to $10 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...